Tumor Genomic Event Prediction Using Concerted Effect Burden
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor classification methods lack a unified standard for quantitatively evaluating tumor genomic characteristics, leading to inconsistent and vague indicators like TMB, which complicates treatment and management of tumors with genomic heterogeneity.
Innovation Solution
A method and electronic apparatus that integrate global mutant information to establish a comprehensive quantitative index for intracellular deterministic events, using concerted effect and concerted effect burden parameters to describe gene expression activity, enabling standardized analysis of tumor microevolution and differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If TMB is used as a tumor evaluation indicator, then tumor genomic characteristics can be described, but the indicator becomes vague and inconsistent across different institutions and cancer types
Solution Approach 1:
The patent transforms the discrete TMB parameter into a continuous intracellular deterministic event parameter through mathematical transformation. This allows the indicator to maintain measurement precision while becoming adaptable across different cancer types by establishing universal thresholds based on intracellular deterministic event characteristics rather than institution-specific TMB counts
Solution Approach 2:
The patent creates a universal evaluation system that can assess tumor genomic characteristics across all cancer types using the same intracellular deterministic event parameter. This single parameter serves multiple functions: describing tumor genomic heterogeneity, predicting treatment response, and providing standardized thresholds applicable to pan-cancer species
2Measurement precision
If institution-specific TMB counting methods are used, then tumor characteristics can be measured, but the values differ across institutions making universal standards impossible
Solution Approach 1:
The patent changes the measurement parameter from discrete mutation counts to continuous intracellular deterministic event parameters. This transformation enables standardized calculation methods that produce consistent results across different institutions while maintaining the ability to accurately reflect tumor genomic characteristics
Solution Approach 2:
The patent establishes feedback mechanisms through standardized calculation algorithms and universal thresholds that ensure consistent measurement across institutions. The system continuously refines the intracellular deterministic event parameter calculation based on standardized protocols, ensuring reliability and reproducibility of results across different testing environments
3Adaptability or versatility
If qualitative descriptions like 'relatively high, medium, and low' are used for TMB, then tumor characteristics can be described, but the results are difficult to interpret quantitatively
Solution Approach 1:
The patent transforms qualitative TMB descriptions into a continuous quantitative parameter scale based on intracellular deterministic events. This allows the system to maintain the adaptability of qualitative descriptions while enabling precise quantitative interpretation through standardized thresholds and continuous parameter values
Data Source
AI summary
A method for predicting intracellular deterministic events and an electronic apparatus are provided. The method includes detecting, by the electronic apparatus, global mutant information of mutant genes of a tested sample taken from a target object, converting the global mutant information of mutant genes of the tested sample into concerted effect (CE) parameters with a quantitative mode, and further converting the CE parameters into concerted effect burden (CEB) parameters through statistical algorithms. The method further includes predicting the intracellular deterministic events based on the CEB parameters.